Literature DB >> 25848461

Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Giulia Ganzetti1, Anna Campanati1, Annamaria Offidani1.   

Abstract

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and end-stage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases.

Entities:  

Keywords:  Adipocytokines; Adipose tissue; Biologic therapies; Non-alcoholic fatty liver disease; Non-biologic therapies; Psoriasis

Year:  2015        PMID: 25848461      PMCID: PMC4381160          DOI: 10.4254/wjh.v7.i3.315

Source DB:  PubMed          Journal:  World J Hepatol


  124 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

Review 2.  Psoriasis and its comorbidities.

Authors:  Neh Onumah; Leon H Kircik
Journal:  J Drugs Dermatol       Date:  2012-05       Impact factor: 2.114

3.  Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy.

Authors:  S Coimbra; H Oliveira; F Reis; L Belo; S Rocha; A Quintanilha; A Figueiredo; F Teixeira; E Castro; P Rocha-Pereira; A Santos-Silva
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-12       Impact factor: 6.166

Review 4.  A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

Authors:  Jonathan P Staidle; Tushar S Dabade; Steven R Feldman
Journal:  Expert Opin Pharmacother       Date:  2011-07-08       Impact factor: 3.889

5.  Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study.

Authors:  Sara Lestre; Filipa Diamantino; Luis Veloso; Ana Fidalgo; Ana Ferreira
Journal:  Eur J Dermatol       Date:  2011 Nov-Dec       Impact factor: 3.328

6.  Effects of erdosteine on cyclosporine-A-induced hepatotoxicity in rats.

Authors:  Elife Erarslan; Fuat Ekiz; Burak Uz; Cemile Koca; Ummuhani Ozel Turkcu; Reyhan Bayrak; Tuncay Delibasi
Journal:  Drug Chem Toxicol       Date:  2010-10-18       Impact factor: 3.356

7.  Effect of etanercept on insulin sensitivity in nine patients with psoriasis.

Authors:  M Marra; A Campanati; R Testa; C Sirolla; A R Bonfigli; C Franceschi; F Marchegiani; A Offidani
Journal:  Int J Immunopathol Pharmacol       Date:  2007 Oct-Dec       Impact factor: 3.219

8.  Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.

Authors:  Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand
Journal:  JAMA Dermatol       Date:  2013-10       Impact factor: 10.282

Review 9.  Inflammatory pathways and insulin action.

Authors:  G S Hotamisligil
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

10.  Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.

Authors:  Edmund Cauza; Karla Cauza; Ursula Hanusch-Enserer; Mehrdad Etemad; Attila Dunky; Karam Kostner
Journal:  Wien Klin Wochenschr       Date:  2002-12-30       Impact factor: 1.704

View more
  16 in total

Review 1.  Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.

Authors:  Giulia Ganzetti; Anna Campanati; Elisa Molinelli; Annamaria Offidani
Journal:  World J Cardiol       Date:  2016-02-26

Review 2.  Utility and Limitations of Transient Elastography to Monitor Hepatic Steatosis, Hepatic Fibrosis, and Methotrexate-Associated Hepatic Disease in Psoriasis: A Systematic Review.

Authors:  Rachel L Marsh; Sean Kelly; Khalid Mumtaz; Jessica Kaffenberger
Journal:  J Clin Aesthet Dermatol       Date:  2021-12

Review 3.  Role of MicroRNAs in NAFLD/NASH.

Authors:  Gyongyi Szabo; Timea Csak
Journal:  Dig Dis Sci       Date:  2016-01-14       Impact factor: 3.199

4.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Lisa B VanWagner; Mary E Rinella
Journal:  Curr Hepatol Rep       Date:  2016-03-28

Review 5.  Nonalcoholic fatty liver disease - A multisystem disease?

Authors:  Ivana Mikolasevic; Sandra Milic; Tamara Turk Wensveen; Ivana Grgic; Ivan Jakopcic; Davor Stimac; Felix Wensveen; Lidija Orlic
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

6.  Sneddon-Wilkinson Disease and Monoclonal Gammopathy of Undetermined Significance in the Elderly: Case Report.

Authors:  Gabriele Ceccarelli; Elisa Molinelli; Anna Campanati; Gaia Goteri; Annamaria Offidani
Journal:  Case Rep Dermatol       Date:  2019-07-10

Review 7.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Andrew A Li; Aijaz Ahmed; Donghee Kim
Journal:  Gut Liver       Date:  2020-03-15       Impact factor: 4.519

8.  Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules.

Authors:  Dan Ilkovitch; Laura K Ferris
Journal:  Mol Med Rep       Date:  2016-08-26       Impact factor: 2.952

Review 9.  Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.

Authors:  Che-Yung Chao; Robert Battat; Alex Al Khoury; Sophie Restellini; Giada Sebastiani; Talat Bessissow
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

Review 10.  NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome.

Authors:  Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico
Journal:  Int J Environ Res Public Health       Date:  2019-09-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.